Complicated intra-abdominal infections Infections and Infestations Other and unspecified infectious diseases
Conditions
Interventions
Current information as of 13/08/09:
Adult patients with intra-abdominal infections requiring surgery were eligible for this open-label randomized trial comparing ertapenem 1 g daily with ceftriaxone 2
Sponsors
Merck and Co., Inc. (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current information as of 13/08/09: 1. Male or female patients aged 18 or over 2. Patient has a diagnosis of intra-abdominal infection requiring surgery as evidenced by fever, elevated while blood cell count and abdominal pain Initial information at time of registration: Adult patients with intra-abdominal infections requiring surgery
Exclusion criteria
Exclusion criteria: Added 13/08/09: 1. Patient has another infection, other than abdominal 2. Female patient is pregnant or planning to become pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added 13/08/09: Efficacy as measured by clinical response rate in clinically and microbiologically evaluable participants at the test-of-cure (TOC) visit 2 weeks after discontinuation of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Added 13/08/09: Efficacy measured at TOC visit 4 weeks after discontinuation of therapy | — |
Countries
Philippines
Outcome results
None listed